(NASDAQ: COCP) Cocrystal Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 56.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 101.52%.
Cocrystal Pharma's earnings in 2025 is -$12,561,000.On average, 5 Wall Street analysts forecast COCP's earnings for 2025 to be -$8,615,396, with the lowest COCP earnings forecast at -$8,646,172, and the highest COCP earnings forecast at -$8,617,447. On average, 5 Wall Street analysts forecast COCP's earnings for 2026 to be -$9,173,478, with the lowest COCP earnings forecast at -$11,260,131, and the highest COCP earnings forecast at -$6,570,804.
In 2027, COCP is forecast to generate -$11,405,807 in earnings, with the lowest earnings forecast at -$10,958,521 and the highest earnings forecast at -$11,741,272.